CoChat

Research progress of T cells in cholangiocarcinoma

Open access
Wang, Zhiming, Dai, Yunyan, Zhou, Yunpeng, Wang, Yi, Chen, Pinggui, Li, Yaoxuan, Zhang, Yunfei, Wang, Xiaocui, Hu, Ying, Li, Haonan, Li, Gaopeng, Jing, Yukai · 2025 · Frontiers in Immunology

The DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.

Abstract

Cholangiocarcinoma (CCA), a malignant tumor, is typically challenging to detect early and often results in a poor prognosis. In recent years, research interest has grown in the potential application of immunotherapy for CCA treatment. T cells, as a crucial component of the immune system, play a significant role in immune surveillance and therapy for cholangiocarcinoma. This article provides a review of the research advancements concerning T cells in cholangiocarcinoma patients, including their distribution, functional status, and correlation with patient prognosis within the tumor microenvironment. It further discusses the potential applications and challenges of immunotherapy strategies targeting T cells in CCA treatment and anticipates future research directions. A more profound understanding of T cells’ role in cholangiocarcinoma can guide the development of clinical treatment strategies, thereby enhancing patient survival rates and quality of life. Finally, we explored the potential risks and side effects of immunotherapy for T-cell cholangiocarcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2025.1453344

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 List of ICs and their receptors in CCA. Cholangiocarcinoma cells achieve immune escape by interacting with immune checkpoints on CD8+T cells. ICs, immune checkpoints;B7H4, B7 homolog 4; B7H4R, B7H4 receptor; PD1, programmed cell death protein-1;PDL1, programmed cell death ligand-1; CEACAM, the carcinoembryonic antigen-related adhesion molecules; MHC II, major histocompatibility complex class II; GITR, Glucocorticoid-Induced TNF-related protein; GITRL, GITR ligand; TIM3, T cell immunoglobulin and mucin domain-containing protein 3;CTLA-4, cytotoxic T-lymphocyte associated protein 4; TIGIT, T-cell immunoglobulin and ITIM domain; LAG-3, lymphocyte activation gene 3. By FigDraw.
Figure 1 List of ICs and their receptors in CCA. Cholangiocarcinoma cells achieve immune escape by interacting with immune checkpoints on CD8+T cells. ICs, immune checkpoints;B7H4, B7 homolog 4; B7H4R, B7H4 receptor; PD1, programmed cell death protein-1;PDL1, programmed cell death ligand-1; CEACAM, the carcinoembryonic antigen-related adhesion molecules; MHC II, major histocompatibility complex class II; GITR, Glucocorticoid-Induced TNF-related protein; GITRL, GITR ligand; TIM3, T cell immunoglobulin and mucin domain-containing protein 3;CTLA-4, cytotoxic T-lymphocyte associated protein 4; TIGIT, T-cell immunoglobulin and ITIM domain; LAG-3, lymphocyte activation gene 3. By FigDraw.CC BY · PubMed Central
Figure 2 Immunotherapeutic approaches for T-lymphocyte-associated CCA. (A) CAR-T cell therapy. (B) Immune checkpoint inhibitors for cholangiocarcinoma in clinical studies or early stage trials. (C) Specific peptide vaccination therapy. (D) AllogeneicγδT cell immunotherapy. By FigDraw.
Figure 2 Immunotherapeutic approaches for T-lymphocyte-associated CCA. (A) CAR-T cell therapy. (B) Immune checkpoint inhibitors for cholangiocarcinoma in clinical studies or early stage trials. (C) Specific peptide vaccination therapy. (D) AllogeneicγδT cell immunotherapy. By FigDraw.CC BY · PubMed Central
Figure 3 Preparation of CAR-T cells. (1) isolation: PBMCs were collected from peripheral blood of patients or donors; (2) modification: T cells were activated and CAR was transduced into activated T cells by lentivirus; (3) expansion: modified T cells were expanded in vitro to obtain clinically relevant cell counts; (4) reinfusion: modified T cells at the desired dosage were reinfused into patients who were previously lymphocyte-depleted. By FigDraw.
Figure 3 Preparation of CAR-T cells. (1) isolation: PBMCs were collected from peripheral blood of patients or donors; (2) modification: T cells were activated and CAR was transduced into activated T cells by lentivirus; (3) expansion: modified T cells were expanded in vitro to obtain clinically relevant cell counts; (4) reinfusion: modified T cells at the desired dosage were reinfused into patients who were previously lymphocyte-depleted. By FigDraw.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 140 references

Research works printed but not linked: 1

  1. Zheng, 2023, The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery, Cancer, 129, 393, 10.1002/cncr.v129.3 · doi:10.1002/cncr.v129.3

Metadata

Authors
Wang, Z., Dai, Y., Zhou, Y., Wang, Y., Chen, P., Li, Y., Zhang, Y., Wang, X., Hu, Y., Li, H., Li, G., & Jing, Y.
Affiliations
Shanxi Medical University (CN)
Corresponding author
  • Li, Gaopeng
  • Jing, Yukai
Venue
Frontiers in Immunology
Published
2025-02-25
Volume
16
Pages
1453344-1453344
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4407929136
Cited by
2
References
141
Citations by year
2026: 1 · 2025: 1
FWCI
0.48
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
cholangiocarcinoma, T cells, tumor microenvironment, cancer immunotherapy, T cell distribution, T cell function, prognosis, immune surveillance, immunotherapy side effects
MeSH terms
Animals, Bile Duct Neoplasms, Humans, Immunotherapy, Prognosis, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Cholangiocarcinoma, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Research progress of T cells in cholangiocarcinoma. https://app.cochat.ai/papers/10.3389/fimmu.2025.1453344
The paper
Wang, Z., Dai, Y., Zhou, Y., Wang, Y., Chen, P., Li, Y., Zhang, Y., Wang, X., Hu, Y., Li, H., Li, G., & Jing, Y. (2025). Research progress of T cells in cholangiocarcinoma. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1453344

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.